specific proteins or specific oligopeptides or a degree of activity thereof in a certain number of biological samples derived from healthy and diseased patients are measured in advance, and a range of abnormal value and a range of normal value are decided. Next, a biological sample to be evaluated is measured by the same method, and examination evaluation is performed depending on whether the measurement result belongs to any of the decided range of abnormal value and the decided range of normal value.

[0003]

Regarding biomarkers used for detecting cognitive impairment, for example, Patent Literature 1 below discloses (a) a biomarker for detecting a cognitive impairment disease consisting of an intact protein of Apolipoprotein A1 containing an amino acid sequence represented by SEQ ID NO: 1 or a partial peptide thereof, (b) a biomarker for detecting a cognitive impairment disease consisting of an intact protein of Transthyretin containing an amino acid sequence represented by SEQ ID NO: 2 or a partial peptide thereof, and (c) a biomarker for detecting a cognitive impairment disease consisting of an intact protein of Complement C3 containing an amino acid sequence represented by SEQ ID NO: 3 or a partial peptide thereof.

Citation List

Patent Literature

[0004]

Patent Literature 1: International Publication No. 2014-207888

Summary ~~of Invention~~

Technical Problem

[0005]

An object of the present technology is to provide a technique for accurately determining cognitive impairment, cognitive decline, or risk of any of them. Cognitive impairment refers to a stage of mild cognitive impairment (hereinafter also referred to as MCI) or a stage of dementia.

Solution to Problem

[0006]

The present inventor has found that specific determination supporting information is suitable for accurately determining cognitive impairment, cognitive decline, or risk of any of them. The inventor has also found that certain biomarker combinations are suitable for accurately determining cognitive impairment, cognitive decline, or risk of any of them.

[0007]

The present disclosure refers to subject matter as defined in the attached set of claims.

That is, the present technology provides

a determination supporting information generating method, comprising:

an index value calculating step of calculating, based on amounts of two or more biomarkers contained in a biological sample derived from a human,

(I) a first index value indicating the presence or absence of cognitive impairment or cognitive decline in the human and

(II) a second index value indicating the degree of progression of cognitive impairment or cognitive decline in the human; and

a supporting information generating step of generating information that supports determination of cognitive impairment, cognitive decline, or risk of any of them, based on the first index value and the second index value.